11.55
-0.20 (-1.70%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | Third Harmonic Bio, Inc. | Bearish | Bullish |
Stockmoo Score
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company’s product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract. |
|
Sector | Healthcare |
Industry | Biotechnology |
52 Weeks Range | ||
Price Target Range | ||
High | 23.00 (Stifel, 99.13%) | Buy |
Median | 21.50 (86.15%) | |
Low | 20.00 (Morgan Stanley, 73.16%) | Buy |
Average | 21.50 (86.15%) | |
Total | 2 Buy | |
Avg. Price @ Call | 12.22 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Morgan Stanley | 09 Aug 2024 | 20.00 (73.16%) | Buy | 12.12 |
Stifel | 18 Jun 2024 | 23.00 (99.13%) | Buy | 12.32 |
No data within this time range.
Date | Type | Details |
---|---|---|
10 Sep 2024 | Announcement | Third Harmonic Bio to Participate in Upcoming Investor Conferences in September |
26 Aug 2024 | Announcement | Third Harmonic Bio to Participate in Upcoming Investor Conferences |
08 Aug 2024 | Announcement | Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |